ArticleHeliyon2024
Salivary and serum nitric oxide synthase, macrophage inflammatory protein 1 alpha and macrophage migration inhibitory factor levels in periodontal disease.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Cascade Therapy of Periodontitis via Sequential Release of Ribosome-Targeting Antimicrobial Peptide and Irisin From a Multifunctional MOF-Based System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Causal relationships between 41 inflammatory cytokines and myopia: a Mendelian randomization study.International journal of ophthalmology · 2026Article
- Role of oral and gut microbiomes in enterosalivary nitrate metabolism and their effects on systemic disease.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Periodontal disease is multifactorial inflammatory disease involving both gingivitis and periodontitis. Inducible nitric oxide synthase (iNOS), macrophage inflammatory protein 1 alpha (MIP-1α) and macrophage migration inhibitory factor (MIF) are mediators contributing to the progression of periodontal diseases with distinct functions. The aim of this study is to evaluate the local and systemic iNOS, MIP-1α and MIF concentrations in patients having periodontal disease with different severities. Design: The study was conducted on 88 individuals equally divided into four groups; 1) Periodontally Healthy 2) Gingivitis 3) Stage I-II Periodontitis 4) Stage III-IV Periodontitis. Saliva and serum samples were obtained from each individual and then periodontal examinations were performed. Plaque and bleeding on probing indexes, probing depths and clinical attachment levels were measured on each tooth to determine the periodontal status. Concentrations of iNOS, MIP-1α and MIF were measured with enzyme-linked immunosorbent assay. Results: Patients with stage I-II and stage III-IV periodontitis had more iNOS levels than periodontally healthy people in serum and saliva (p ≤ 0,001 for serum; p < 0,05 for saliva). Stage III-IV periodontitis group had significantly more serum-iNOS levels than that in gingivitis group (p = 0,005). When compared with periodontally healthy individuals, MIP-1α levels in stage III-IV periodontitis patients were measured significantly more in saliva; (p = 0,016) but less in serum (p = 0,006) samples. More serum-MIF concentrations were observed in stage I-II periodontitis groups than that in periodontally healthy individuals (p < 0,05). Conclusion: Increased salivary and serum iNOS and serum-MIF levels in different stages of periodontitis suggest that these molecules might be involved in periodontal disease pathogenesis. Also, oral microenvironment may stimulate the enhanced MIP-1α concentration in advanced periodontitis cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.